The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Background Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been
associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) …

Background: Familial combined hypolipidemia, a Mendelian condition characterized by
substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the …

Triglyceride-rich lipoproteins deliver fatty acids to tissues for oxidation and for storage.
Release of fatty acids from circulating lipoprotein triglycerides is carried out by lipoprotein …

Background: Hypertriglyceridemia is associated with increased cardiovascular risk and may
be caused by impaired lipoprotein clearance. Angiopoietin-like protein 3 (ANGPTL3) inhibits …

The introduction of statins≈ 30 years ago ushered in the era of lipid lowering as the most
effective way to reduce risk of atherosclerotic cardiovascular disease. Nonetheless, residual …

Triglycerides and cholesterol circulate in the bloodstream as part of various lipoprotein
particles. Three members of the angiopoietin-like (ANGPTL) protein family—ANGPTL3 …

Angiopoietin-like protein 3 (ANGPTL3) is a circulating protein synthesized exclusively in the
liver that inhibits LPL and endothelial lipase (EL), enzymes that hydrolyze TGs and …

Optimal management of low-density lipoprotein cholesterol (LDL-C) is a central tenet in the
primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) …